Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome

Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, 4, 295, 10.1111/j.1538-7836.2006.01753.x Ruiz-Irastorza, 2011, Lupus and pregnancy: integrating clues from the bench and bedside, Eur J Clin Invest, 41, 672, 10.1111/j.1365-2362.2010.02443.x Ostensen, 2011, Pregnancy and reproduction in autoimmune rheumatic diseases, Rheumatology (Oxford), 50, 657, 10.1093/rheumatology/keq350 Doria, 2008, Challenges of lupus pregnancies, Rheumatology, 47, iii9, 10.1093/rheumatology/ken151 Imbasciati, 2009, Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome, Nephrol Dial Transplant, 24, 519, 10.1093/ndt/gfn348 Clowse, 2005, The impact of increased lupus activity on obstetrical outcomes, Arthritis Rheum, 52, 514, 10.1002/art.20864 Clowse, 2011, The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus, J Rheumatol, 38, 1012, 10.3899/jrheum.100746 Rahman, 2005, Pregnancy outcome in lupus nephropathy, Arch Gynecol Obstet, 271, 222, 10.1007/s00404-003-0574-x Oviasu, 1991, The outcome of pregnancy in women with lupus nephritis, Lupus, 1, 19, 10.1177/096120339100100104 Moroni, 2002, Pregnancy in lupus nephritis, Am J Kidney Dis, 40, 713, 10.1053/ajkd.2002.35678 Bramham, 2011, Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis, J Rheumatol, 38, 1906, 10.3899/jrheum.100997 Smyth, 2010, A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis, Clin J Am Soc Nephrol, 5, 2060, 10.2215/CJN.00240110 Tandon, 2004, The effect of pregnancy on lupus nephritis, Arthritis Rheum, 50, 3941, 10.1002/art.20638 Ruiz-Irastorza, 2007, Heart disease, pregnancy and systemic autoimmune diseases, 136 Bonnin, 2005, Severe pulmonary hypertension during pregnancy. Mode of delivery and anesthetic management of 15 consecutive cases, Anesthesiology, 102, 1133, 10.1097/00000542-200506000-00012 Clowse, 2008, A national study of the complications of lupus in pregnancy, Am J Obstet Gynecol, 199, 127.e1, 10.1016/j.ajog.2008.03.012 Salmon, 2011, Mutations in complement regolatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort, PLoS Med, 8, 10.1371/journal.pmed.1001013 Vinet, 2011, Decreased live births in women with systemic lupus erythematosus, Arthritis Care Res (Hoboken), 63, 1068, 10.1002/acr.20466 Clowse, 2006, Early risk factors for pregnancy loss in lupus, Obstet Gynecol, 107, 293, 10.1097/01.AOG.0000194205.95870.86 Yan Yuen, 2008, Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: results from a case control study and literature review, Open Rheumatol J, 2, 89, 10.2174/1874312900802010089 Clark, 2003, Preterm deliveries in women with systemic lupus erythematosus, J Rheumatol, 30, 2127 Stagnaro-Green, 2011, Thyroid disease in pregnant women with systemic lupus erythematosus: increased preterm delivery, Lupus, 20, 690, 10.1177/0961203310394894 Johnson, 1995, Evaluation of preterm delivery in a systemic lupus erythematosus pregnancy clinic, Obstet Gynecol, 86, 396, 10.1016/0029-7844(95)00186-U Magid, 1998, Placental pathology in systemic lupus erythematosus: a prospective study, Am J Obstet Gynecol, 179, 226, 10.1016/S0002-9378(98)70277-7 Le Thi Houng, 2006, The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome, Rheumatology (Oxford), 45, 332, 10.1093/rheumatology/kei159 Castellino, 2006, Uterine artery Doppler in predicting pregnancy outcome in women with connective tissue disorders, Rheumatology (Oxford), 45, 1174, 10.1093/rheumatology/kel212 Silverman, 2010, Non-cardiac manifestations of neonatal lupus erythematosus, Scand J Immunol, 72, 223, 10.1111/j.1365-3083.2010.02443.x Prendville, 2003, Central nervous system involvement in neonatal lupus erythematosus, Ped Dermatol, 20, 60, 10.1046/j.1525-1470.2003.03014.x Motta, 2011, Cerebral ultrasound abnormalities in infants born to mothers with autoimmune disease, Arch Dis Child Fetal Neonatal, 96, F355, 10.1136/adc.2010.195099 Hornberger, 2010, Spectrum of cardiac involvement in neonatal lupus, Scand J Immunol, 72, 189, 10.1111/j.1365-3083.2010.02437.x Guettrot-Imbert, 2011, A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal anti-SSA/Ro and anti-SSB/La antibodies, J Rheumatol, 38, 378, 10.3899/jrheum.100317 Brucato, 2011, Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies, Clin Rev Allergy Immunol, 40, 27, 10.1007/s12016-009-8190-6 Ambrosi, 2011, Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern, Ann Rheum Dis, 10.1136/ard.2010.149021.14 Llanos, 2009, Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors, Arthritis Rheum, 60, 3091, 10.1002/art.24768 Izmirly, 2010, Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block, Arthritis Rheum, 62, 1153, 10.1002/art.27333 Salomonsson, 2010, Autoantibodies associated with congenital heart block, Scand J Immunol, 72, 185, 10.1111/j.1365-3083.2010.02442.x Strandberg, 2008, Antibodies to amino acid 200–239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block, Clin Exp Immunol, 154, 30, 10.1111/j.1365-2249.2008.03732.x Strandberg, 2010, Maternal MHC regulates generation of pathogenic autoantibodies and fetal MHC-encoded genes determine susceptibility in congenital heart block, J Immunol, 185, 3574, 10.4049/jimmunol.1001396 Clancy, 2010, Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus, Arthritis Rheum, 62, 3415, 10.1002/art.27658 Brucato, 2010, Passively acquired anti-SSA/Ro antibodies are required for congenital heart block following ovodonation but maternal genes are not, Arhtritis Rheum, 62, 3119, 10.1002/art.27575 Izmirly, 2010, Evaluation of the risk of anti-SSA/Ro–SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine, Ann Rheum Dis, 69, 1827, 10.1136/ard.2009.119263 Brucato, 2008, Prevention of congenital heart block in children of SSA-positive mothers, Rheumatology (Oxford), 47, i35, 10.1093/rheumatology/ken153 Sonesson, 2010, Diagnosing foetal atrioventricular heart blocks, Scand J Immunol, 72, 205, 10.1111/j.1365-3083.2010.02434.x Mevorach, 2009, Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block, Curr Opin Rheumatol, 21, 478, 10.1097/BOR.0b013e32832ed817 Friedman, 2008, Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR interval and dexamethasone evaluation (PRIDE), Circulation, 117, 485, 10.1161/CIRCULATIONAHA.107.707661 Jaeggi, 2011, Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses, J Am Coll Cardiol, 57, 1487, 10.1016/j.jacc.2010.12.014 Hutter, 2010, The benefits of transplacental treatment of isolated congenital complete heart block associated with maternal anti-Ro/SSA antibodies: a review, Scand J Immunol, 72, 235, 10.1111/j.1365-3083.2010.02440.x Friedman, 2009, Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR interval and dexamethasone evaluation (PRIDE) study, Am J Cardiol, 103, 1102, 10.1016/j.amjcard.2008.12.027 Costedoat-Chalumeau, 2003, Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block, Ann Rheum Dis, 62, 1010, 10.1136/ard.62.10.1010 Tran, 2004, Intravenous immunoglobulin and placental transport of anti-Ro/La antibodies: comment on the letter by Kaaja and Julkunen, Arthritis Rheum, 50, 337, 10.1002/art.11498 Friedman, 2010, Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial, Arthritis Rheum, 62, 1138, 10.1002/art.27308 Pisoni, 2010, Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study, Arthritis Rheum, 62, 1147, 10.1002/art.27350 Routsias, 2011, Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block, Arthritis Rheum, 63, 2783, 10.1002/art.30464 Makino, 2007, Effect of steroid administration and plasmapheresis to prevent fetal congenital heart block in patients with systemic lupus erythematosus and/or Sjögren’s syndrome, Acta Obstet Gynecol Scand, 86, 1145, 10.1080/00016340701343024 Biggioggero, 2010, The geoepidemiology of the antiphospholipid syndrome, Autoimmun Rev, 9, A299, 10.1016/j.autrev.2009.11.013 Tincani, 2008, Lupus and the antiphospholipid sindrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment, Semin Thromb Hemost, 34, 267, 10.1055/s-0028-1082270 Pierangeli, 2011, ‘Criteria’ aPL tests: report of a task force and preconference workshop at the 13th international Congress on antiphospholipid antibodies, Galveston, Texas, April 2010, Lupus, 182, 10.1177/0961203310395055 Pierangeli, 2008, Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanism, Semin Thromb Hemost, 34, 236, 10.1055/s-0028-1082267 Out, 1991, Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies, Eur J Obstet Gynecol Reprod Biol, 41, 179, 10.1016/0028-2243(91)90021-C La Rosa, 1994, Beta2glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome, J Rheumatol, 1684 Meroni, 2011, Pathogenesis of antiphospholipid syndrome: understanding the antibodies, Nat Rev Rheumatol, 7, 330, 10.1038/nrrheum.2011.52 Agostinis, 2011, In vivo distribution of beta2glycoprotein I under various pathophysiological conditions, Blood, 118, 4231, 10.1182/blood-2011-01-333617 Personal communication of Prof. Pier Luigi Meroni. Rand, 2010, The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis, Lupus, 19, 460, 10.1177/0961203310361485 Di Simone, 2005, Pathogenic role of anti-beta2glycoprotein I antibodies in antiphospholipid-associated fetal loss: characterisation of beta2glycoprotein I binding to trophoblast cells and functional effects of anti-beta2glycoprotein I antibodies in vitro, Ann Rheum Dis, 64, 462, 10.1136/ard.2004.021444 Ostertag, 2006, A peptide that mimics the Vth region of beta2glycoprotein I reverses antiphospholipid mediated thrombosis in mice, Lupus, 15, 358, 10.1191/0961203306lu2315oa Martinez de la Torre, 2008, Pregnant naïve mice are protected from aPL-induced fetal loss by the injection of a synthetic peptide (TIFI) mimicking the beta2GPI PL-binding site, Arthritis Rheum, 58 Shoenfeld, 2001, Induction and treatment of the antiphospholipid syndrome – lessons from animal models, Eur J Clin Invest, 31, 736, 10.1046/j.1365-2362.2001.00866.x Redecha, 2008, Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome, J Clin Invest, 118, 3453 Holers, 2002, Complement C3 activation is required for antiphospholipid antibody-induced fetal loss, J Exp Med, 195, 211, 10.1084/jem.200116116 Thurman, 2005, A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice, Mol Immunol, 42, 87, 10.1016/j.molimm.2004.07.043 Girardi, 2004, Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation, Nature Med, 10, 1222, 10.1038/nm1121 Empson, 2005, Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant, Cochrane Database Syst Rev, 2, 10.1002/14651858.CD002859.pub2 Cavazzana, 2007, Complement activation in antiphospholipid syndrome: a clue for an inflammatory process?, J Autoimmun, 28, 160, 10.1016/j.jaut.2007.02.013 Shamonki, 2007, Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies, Am J Obstet Gynecol, 196, e1, 10.1016/j.ajog.2006.10.879 Gerosa, 2009, Complement involvement in antiphospholipid antibody-mediated placental damage: prospective study in APS pregnant women, Ann Rheum Dis, 68 Clark, 2007, Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?, Curr Rheumatol Rep, 9, 219, 10.1007/s11926-007-0035-9 Appenzeller, 2011, HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies, Semin Arthritis Rheum, 10.1016/j.semarthrit.2011.05.007 Tincani, 2009, Neonatal effects of maternal antiphospholipid syndrome, Curr Rheumatol Rep, 11, 70, 10.1007/s11926-009-0010-8 Branch, 2011, Obstetric task force report of the obstetric APS task force: 13th international congress on antiphospholipid antibodies, 13th April 2010, Lupus, 20, 158, 10.1177/0961203310395054 Shoenfeld, 1998, Interleukin-3 and pregnancy loss in antiphospholipid syndrome, Scand J Rheumatol Suppl, 107, 19, 10.1080/03009742.1998.11720701 Erkan, 2008, Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers, Rheumatology (Oxford), 47, iii23 Ruffatti, 2011, Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study, Rheumatology (Oxford), 50, 1684, 10.1093/rheumatology/ker139 Urbanus, 2009, Antiphospholipid syndrome and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study, Lancet Neurol, 8, 998, 10.1016/S1474-4422(09)70239-X Østensen, 2006, Anti-inflammatory and immunosuppressive drugs and reproduction, Arthritis Res Ther, 8, 209, 10.1186/ar1957 Østensen, 2008, Update on safety of biological agents and some immunosuppressive anti-rheumatic drugs, Rheumatology, 47, iii28 Li, 2003, Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study, Br Med J, 327, 368 Nielsen, 2001, Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study, BMJ, 322, 266, 10.1136/bmj.322.7281.266 Nakhai-Pour, 2011, Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion, CMAJ, 183, 1713, 10.1503/cmaj.110454 Keim, 2006, Aspirin use and miscarriage risk, Epidemiology, 17, 435, 10.1097/01.ede.0000221693.72971.b3 Kozer, 2003, Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis, Birth Defects Res B Dev Reprod Toxicol, 68, 70, 10.1002/bdrb.10002 Hart, 1964, The ototoxicity of chloroquine phosphate, Arch Otolaryngol, 80, 407, 10.1001/archotol.1964.00750040419009 Levy, 2001, Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study, Lupus, 10, 401, 10.1191/096120301678646137 1980, Successful pregnancies in women treated by dialysis and kidney transplantation, Br J Obstet Gynaecol, 87, 839, 10.1111/j.1471-0528.1980.tb04434.x Polifka, 2002, Teratogen update: azathioprine and 6-mercaptopurine, Teratology, 65, 240, 10.1002/tera.10043 Goldstein, 2007, Pregnancy outcome of women exposed to azathioprine during pregnancy, Birth Defects Res A Clin Mol Teratol, 79, 696, 10.1002/bdra.20399 Clearly, 2009, Early pregnancy azathioprine use and pregnancy outcomes, Birth Defects Res A Clin Mol Teratol, 85, 647, 10.1002/bdra.20583 Hutson, 2011, The transfer of 6-mercaptopurine in the dually perfused human placenta, Reprod Toxicol, 32, 349, 10.1016/j.reprotox.2011.08.008 Lee, 2011, 6-Mercaptopurine transport by equilibrative nucleoside transporters in conditionally immortalized rat syncytiotrophoblast cell lines TR-TBTs, J Pharm Sci, 100, 3773, 10.1002/jps.22631 Pham, 2008, Rituximab (MabThera) therapy and safety management. Clinical tool guide, Joint Bone Spine, 75, S1 Chakravarty, 2011, Pregnancy outcomes after maternal exposure to rituximab, Blood, 117, 1499, 10.1182/blood-2010-07-295444 2011 Bates, 2008, American College of Chest Physicians venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition), Chest, 133, 844S, 10.1378/chest.08-0761 Duhl, 2007, Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes, Am J Obstet Gynecol, 197, 457.e1, 10.1016/j.ajog.2007.04.022 Henderson, 2011, Prescribing in pregnancy and during breast feeding: using principles in clinical practice, Postgrad Med J, 87, 349, 10.1136/pgmj.2010.103606 Ostensen, 2007, Therapy insight: the use of antirheumatic drugs during nursing, Nat Clin Pract Rheumatol, 3, 4000, 10.1038/ncprheum0532 Ito, 2000, Drug therapy for breast-feeding woman, N Engl J Med, 343, 118, 10.1056/NEJM200007133430208 Ostensen, 2004, Disease specific problems related to drug therapy in pregnancy, Lupus, 13, 746, 10.1191/0961203303lu2004oa Clowse, 2005, Cyclophosphamide for lupus during pregnancy, Lupus, 14, 593, 10.1191/0961203305lu2169oa Yazdany, 2011, Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?, Arthritis Care Res, 63, 358 Ostensen, 2011, Connective tissue diseases: contraception counselling in SLE—an often forgotten duty?, Nat Rev Rheumatol, 7, 315, 10.1038/nrrheum.2011.54 Culwell, 2009, Safety of contraceptive method use among women with systemic lupus erythematosus. A systematic review, Obstet Gynecol, 114, 341, 10.1097/AOG.0b013e3181ae9c64 Campbell, 2007, Intrauterine device use in a high-risk population: experience from an urban university clinic, Am J Obstet Gynecol, 197, 193.e1, 10.1016/j.ajog.2007.04.028 Stringer, 2007, A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus, Am J Obstet Gynecol, 197, 144.e1, 10.1016/j.ajog.2007.03.031 Cutolo, 2008, Oestrogens in rheumatic diseases: friend or foe?, Rheumatology (Oxford), 47, iii2, 10.1093/rheumatology/ken150 Sánchez-Guerrero, 2005, A trial of contraceptive methods in women with systemic lupus erythematosus, N Engl J Med, 353, 2539, 10.1056/NEJMoa050817 Petri, 2005, Combined oral contraceptives in women with systemic lupus erythematosus, N Engl J Med, 353, 2550, 10.1056/NEJMoa051135 Askanase, 2002, Buyon JP. Reproductive health in SLE, Best Pract Res Clin Rheumatol, 16, 265, 10.1053/berh.2002.0225 Chabbert-Buffet, 2011, Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients, Contraception, 83, 229, 10.1016/j.contraception.2010.08.012 Kaunitz, 2008, Bone density recovery after depot medroxyprogesterone acetate injectable contraception use, Contraception, 77, 67, 10.1016/j.contraception.2007.10.005 Gai, 2011, The effect of depot medroxyprogesterone acetate DMPA on bone mineral density BMD and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age, Contraception, 83, 218, 10.1016/j.contraception.2010.07.027 Hardy, 1999, Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study, Rheumatology, 38, 559, 10.1093/rheumatology/38.6.559 Hickman, 2011, Causes and management of infertility in systemic lupus erythematosus, Rheumatology (Oxford), 50, 1551, 10.1093/rheumatology/ker105 Packham, 1992, Lupus nephritis and pregnancy, Quarterly Journal of Medicine, 83, 315 Silva, 2010, Maintanance of fertility in patients with rheumatic diseases needing antiinflammatory and immunosuppressive drugs, Arthritis Care Res, 62, 1682, 10.1002/acr.20323 Blumenfeld, 2011, Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases, Semin Arthritis Rheum, 10.1016/j.semarthrit.2011.05.008 Micu, 2011, Luteneized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropaties, Arthritis Care Res, 63, 1334, 10.1002/acr.20510 Guballa, 2000, Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome, Arthritis Rheum, 43, 550, 10.1002/1529-0131(200003)43:3<550::AID-ANR10>3.0.CO;2-Y Le Thi Huong, 2002, Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles, Semin Arthritis Rheum, 32, 174, 10.1053/sarh.2002.37212 Bellver, 2009, Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid sindrome, Fertil Steril, 92, 1803, 10.1016/j.fertnstert.2009.06.033 Udoff, 2000, Management of patients with antiphospholipid antibodies undergoing in vitro fertilization, J Autoimmun, 15, 209, 10.1006/jaut.2000.0416 Tincani, 2006, Impact of in utero environment on the offspring of lupus patients, Lupus, 15, 801, 10.1177/0961203306071005 Parke, 2006, Drug exposure, pregnancy outcome and fetal and childhood development occurring in the offspring of mothers with systemic lupus erythematosus and other chronic autoimmune diseases, Lupus, 15, 808, 10.1177/0961203306071003 Fang, 2005, Management of preterm infants with intrauterine growth restriction, Early Hum Dev., 81, 889, 10.1016/j.earlhumdev.2005.09.004 Skog, 2008, Outcome and growth of infants fetally exposed to heart block-associated maternal anti-Ro52/SSA autoantibodies, Pediatrics, 121, e803, 10.1542/peds.2007-1659 Izmirly, 2011, Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus, Circulation, 124, 1927, 10.1161/CIRCULATIONAHA.111.033894 Bomba, 2010, Neuropsychiatric aid in children born to patients with rheumatic diseases, Clin Exp Rheumatol, 28, 767 Urowitz, 2008, Neurocognitive abnormalities in offspring of mothers with systemic lupus erythematosus, Lupus, 17, 555, 10.1177/0961203308089326 Neri, 2004, Neuropsychological development of children born to patients with systemic lupus erythematosus, Lupus, 13, 805, 10.1191/0961203304lu2018oa Wolin, 1984, The Ro small cytoplasmic ribonucleoproteins: identification of the antigenic protein and its binding site on the Ro RNAs, Proc Natl Acad Sci U S A, 81, 1996, 10.1073/pnas.81.7.1996 Ross, 2003, Effects of mothers’ autoimmune disease during pregnancy on learning disabilities and hand preference in their children, Arch Pediatr Adolesc Med, 157, 397, 10.1001/archpedi.157.4.397 Behan, 1985, Anti-Ro antibody in mothers of dyslexic children, Dev Med Child Neurol, 27, 538, 10.1111/j.1469-8749.1985.tb04582.x Brucato, 2006, Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero, Ann Rheum Dis, 65, 1422, 10.1136/ard.2005.049866 Askanase, 2010, Frequency of neuro-psychiatric dysfunction in anti-SSA/SSB exposed children with and without neonatal lupus, Lupus, 19, 300, 10.1177/0961203309354542 Nacinovich, 2008, Neuropsychological development of children born to patients with antiphospholipid syndrome, Arthritis Rheum, 59, 345, 10.1002/art.23311 Motta, 2010, European registry of infants born to mothers with antiphospholipid syndrome: preliminary results, Minerva Pediatr, 62, 25 Motta, 2008, Follow-up of children exposed antenatally to immunosuppressive drugs, Rheumatology (Oxford), 47, iii32 Cimaz, 2007, Response to tetanus vaccination in infants exposed in utero to immunosuppressants for maternal autoimmune disorders, Lupus, 16, 129, 10.1177/0961203306075738 Cimaz, 2004, Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy, Toxicol Lett, 149, 155, 10.1016/j.toxlet.2003.12.030 Motta, 2007, Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents, Am J Perinatol, 24, 441, 10.1055/s-2007-986679 Airò, 2006, Characterization of T-cell population with prolonged fetal exposure to dexamethasone for anti-Ro/SS-A antibodies associated congenital heart block, Lupus, 15, 553, 10.1177/0961203306071869 Motta, 2006, Anticardiolipin and anti-beta2 glycoprotein I antibodies in infants born to mothers with antiphospholipid antibody-positive autoimmune disease: a follow-up study, Am J Perinatol, 23, 247, 10.1055/s-2006-939533 Andreoli, 2011, Anti-β₂-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile?, Ann Rheum Dis, 70, 380, 10.1136/ard.2010.137281